Drug Profile

AGA 2115

Alternative Names: AGA-2115

Latest Information Update: 18 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Angitia Biopharmaceuticals
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Osteogenesis imperfecta
New Molecular Entity Yes

Highest Development Phases

Phase I Osteogenesis imperfecta

Most Recent Events

12 Jun 2025 AGA 2115 receives Orphan Drug status for Osteogenesis imperfecta in European Union
12 Jun 2025 Pharmacodynamics and adverse events data from a phase-I trial in osteogenesis imperfecta (In volunteers) released by Angitia Biopharmaceuticals
12 Jun 2025 Angitia Biopharmaceuticals plans phase-II trial for Osteogenesis imperfecta (In adults, In children)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com